The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

TGF-beta as a target for novel analgesics


Stanford Reference:

10-033


Abstract


Researchers in the Pasricha laboratory at Stanford have shown that antagonists to transforming growth factor-β (TGF-β) could be used to treat pain because TGF-β plays a direct role in sensitizing nociceptors (pain-sensing neurons). TGF-β is known to be upregulated in most cases of chronic inflammation and to contribute to local tissue fibrosis. Therefore, targeting this pathway could be particularly useful for conditions such as pancreatitis and arthritis pain where inflammation and fibrosis is prominent.

Stage of Research
The inventors have shown that an antibody antagonist of TGF-β can reduce pain behaviors in a rat model of pancreatitis. In addition, they have shown that TGF-β induces excitability of sensory neurons via specific ion channels that can be blocked by a small molecule inhibitor of TGF-β signaling.

Applications


  • Analgesic for acute and chronic pain

Advantages


  • Non-narcotic
  • Novel, well-characterized pathway

Publications



Innovators & Portfolio



Patent Status



Date Released

 2/7/2013
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

87-057 Endothelial Molecules and the Control of Leukocyte Extravasation - MECA-79 and MECA-367
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

more technologies

Related Keywords


arthritis   chronic pain   osteoarthritis   pain   screening: target   TGF-beta   therapeutic: analgesic   neuropathic pain   nociception   pain management   top pharma companies   
 

   

  

Also of Interest...
87-057 Endothelial Molecules and the Control of Leukocyte Extravasation - MECA-79 and MECA-367
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

Recently Viewed...
S10-033 TGF-beta as a target for novel analgesics